MAYNE PHARMA GROUP LIMITED — Capital/Financing Update 2017

May 1, 2017

==> picture [116 x 45] intentionally omitted <==

ASX Announcement

CLARIFICATION – ASX ANNOUNCEMENT

2 May 2017, Adelaide Australia: Mayne Pharma Group Limited (ASX: MYX) would like to clarify statements made in the ‘Operational Update and Earnings Outlook’ in the Investor Day Presentation released to the ASX on 1 May 2017. As noted in the Presentation, the tougher pricing environment for generics in the US in FY17 is expected to result in FY17 Teva portfolio sales being less than the guidance given at the time of the acquisition of the Teva portfolio. However, as also noted, the gross profit margin percentage on sales of the Teva portfolio is presently ahead of guidance and FY17 EBITDA on the portfolio is expected to be broadly in line with guidance. Accordingly, the reduction in sales from the Teva portfolio is not expected to have a material impact on overall FY17 EBITDA.

For further information contact:

Lisa Pendlebury +61 419 548 434, lisa.pendlebury@maynepharma.com

About Mayne Pharma

Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on applying its drug delivery expertise to commercialise branded and generic pharmaceuticals, providing patients with access to better and more affordable medicines. Mayne Pharma also provides contract development and manufacturing services to more than 100 clients worldwide.

Mayne Pharma has a 30-year track record of innovation and success in developing new oral drug delivery systems and these technologies have been successfully commercialised in numerous products that have been marketed around the world.

Mayne Pharma has two product development and manufacturing facilities based in Salisbury, Australia and Greenville, USA with expertise in the formulation of complex oral dose forms including highly potent compounds, controlled substances, modified-release products and inherently unstable compounds.

==> picture [115 x 117] intentionally omitted <==

Page 1